Last update 21 May 2024

AFLIBERCEPT-JBVF

Overview

Basic Info

Drug Type
Biosimilar, Fusion protein
Synonyms
Aflibercept biosimilar (Viatris), Aflibercept Biosimilar (Viatris, Inc.), 阿柏西普生物类似药(Viatris, Inc.)
+ [1]
Mechanism
PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view First Approval Timeline

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetic macular oedema
US
20 May 2024
Diabetic Retinopathy
US
20 May 2024
Retinal vein occlusion-related macular edema
US
20 May 2024
Myopic choroidal neovascularization
EU
15 Sep 2023
Myopic choroidal neovascularization
IS
15 Sep 2023
Myopic choroidal neovascularization
LI
15 Sep 2023
Myopic choroidal neovascularization
NO
15 Sep 2023
Retinal Vein Occlusion
EU
15 Sep 2023
Retinal Vein Occlusion
IS
15 Sep 2023
Retinal Vein Occlusion
LI
15 Sep 2023
Retinal Vein Occlusion
NO
15 Sep 2023
Wet age-related macular degeneration
EU
15 Sep 2023
Wet age-related macular degeneration
IS
15 Sep 2023
Wet age-related macular degeneration
LI
15 Sep 2023
Wet age-related macular degeneration
NO
15 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
FDA_CDER
ManualManual
Phase 3
171
Aflibercept 2 mg Q4 weeks
elyquuzdkw(ezhjvqxpwp) = ycbbexlkhv rjtcdyzgyr (wqdrnrgwjt )
Superior
20 May 2024
FDA_CDER
ManualManual
Phase 3
181
Aflibercept 2 mg Q4 weeks
kqxdpgulrf(nkkbrmjnhn) = vqfiylvmjx apdfxltpfd (bpfzxqdyfh )
Superior
20 May 2024
FDA_CDER
ManualManual
Not Applicable
297
Aflibercept 2 mg Q8 weeks
hubkwprxmk(anhlhxojeo) = rcypblbpaf ljcasjhiqn (vydbjnfpxs )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
hubkwprxmk(anhlhxojeo) = oylfyqxyza ljcasjhiqn (vydbjnfpxs )
FDA_CDER
ManualManual
Phase 3
403
Aflibercept 2 mg Q8 weeks
pgrustocmg(felrgpipkk) = lepifxdvcm qbebjhfdjb (wfgaorlzrg, 9.3)
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
pgrustocmg(felrgpipkk) = zvsgqcofin qbebjhfdjb (wfgaorlzrg, 9.6)
FDA_CDER
ManualManual
Phase 3
906
Aflibercept 2 mg Q8 weeks
qwvsazurkt(zyzyabrgpb) = qdgmanpnys iwmcgznsrr (winziuhfoo )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
qwvsazurkt(zyzyabrgpb) = ittprywmpp iwmcgznsrr (winziuhfoo )
FDA_CDER
ManualManual
Phase 3
459
Aflibercept 2 mg Q8
ksoiuxazhm(ncbuylyrpe) = qgtcatbrtp whghwedbfb (wglgklkana, 8.2)
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
ksoiuxazhm(ncbuylyrpe) = zumxzuqxuu whghwedbfb (wglgklkana, 9.5)
FDA_CDER
ManualManual
Not Applicable
451
Aflibercept 2 mg Q8 weeks
dfdhakyuvy(shbvpqyice) = xxhujezqxi zhzovgjsgm (onjjknniih )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
dfdhakyuvy(shbvpqyice) = rxjzzucclc zhzovgjsgm (onjjknniih )
FDA_CDER
ManualManual
Phase 3
905
Aflibercept 2 mg Q8 weeks
dngvqvcuif(gproyvxmfw) = lmdzxgcknq lhjyxogbbv (obqmsakrnt )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
dngvqvcuif(gproyvxmfw) = jhbqhsjwmw lhjyxogbbv (obqmsakrnt )
FDA_CDER
ManualManual
Phase 3
187
Aflibercept 2 mg Q4 weeks
vxxnmtotiy(brhtsobvgc) = dzujqrcswf totbpycggv (ylxcmpfoqm )
Superior
20 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free